Guggenheim Reiterates Neutral Rating for CRISPR Therapeutics (NASDAQ:CRSP)

Guggenheim reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Friday, Marketbeat Ratings reports.

Several other analysts also recently weighed in on the company. Needham & Company LLC reiterated a buy rating and set a $88.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, June 27th. Piper Sandler reiterated an overweight rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Barclays dropped their price target on CRISPR Therapeutics from $80.00 to $67.00 and set an equal weight rating on the stock in a research note on Thursday, May 9th. Citigroup lowered their target price on CRISPR Therapeutics from $89.00 to $84.00 and set a buy rating on the stock in a research note on Thursday, May 23rd. Finally, JMP Securities restated a market outperform rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, May 9th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $75.71.

CRISPR Therapeutics Trading Down 0.1 %

CRSP opened at $53.95 on Friday. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of -19.83 and a beta of 1.70. CRISPR Therapeutics has a 12 month low of $37.55 and a 12 month high of $91.10. The stock has a fifty day moving average price of $56.69 and a 200-day moving average price of $64.47.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $25.53 million. During the same period last year, the firm posted ($0.67) earnings per share. The company’s quarterly revenue was down 99.5% on a year-over-year basis. On average, equities research analysts forecast that CRISPR Therapeutics will post -5.51 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CRSP. Riggs Asset Managment Co. Inc. boosted its holdings in CRISPR Therapeutics by 66.7% in the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares during the period. Blue Trust Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $32,000. Bourgeon Capital Management LLC boosted its holdings in CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares during the period. NBC Securities Inc. boosted its holdings in CRISPR Therapeutics by 257.6% in the first quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares during the period. Finally, Principal Securities Inc. purchased a new position in CRISPR Therapeutics in the fourth quarter valued at $41,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.